<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075996</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-10280</org_study_id>
    <nct_id>NCT02075996</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With Pomalidomide (Imnovid®)</brief_title>
  <acronym>Poseidon</acronym>
  <official_title>Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional study is to collect data on the efficiency and safety&#xD;
      of pomalidomide in combination with dexamethasone in the routine application&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2014</start_date>
  <completion_date type="Actual">February 4, 2021</completion_date>
  <primary_completion_date type="Actual">February 4, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Discontinuation (TTD)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment (TNT)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse reaction profile</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary malignancies</measure>
    <time_frame>6 years</time_frame>
    <description>long term safety is focused on secondary malignancies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall Survival (OS)</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative dose intensity of pomalidomide and dexamethasone</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>assess changes in myeloma-related quality of life</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>explore additional supportive therapies</measure>
    <time_frame>3 years</time_frame>
    <description>To explore additional supportive therapies used on this patient population (e.g. G-CSF, antibiotics, DVT prophylaxis)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">151</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Pomalidomide following lenalidomide</arm_group_label>
    <description>75 patients with pomalidomide directly following lenalidomide treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pomalidomide following other therapy</arm_group_label>
    <description>75 patients with pomalidomide following any other prior therapy. This includes lenalidomide in earlier lines than the most recent line.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with relapsing or refractory multiple myeloma previously treated with at&#xD;
        least two prior lines of therapy, including bortezomib and lenalidomide who have progressed&#xD;
        under their last therapy regimen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with relapsed or refractory multiple myeloma Patients must have received at&#xD;
             least two prior lines of treatment (induction therapy followed by stem cell&#xD;
             transplantation ± maintenance therapy is considered one prior therapy) and must have&#xD;
             progressed under the most recent therapy regimen&#xD;
&#xD;
          -  Adult male and female patients (at least 18 years with no upper age limit)&#xD;
&#xD;
          -  Written informed consent to data collection and pseudonymized data transfer&#xD;
&#xD;
          -  The conditions of the Pregnancy Prevention Programme must be fulfilled for all&#xD;
             patients unless there is reliable evidence that the patient does not have childbearing&#xD;
             potential (see summary of product characteristics Imnovid®)&#xD;
&#xD;
          -  Other criteria according to summary of product characteristics Imnovid®&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing patient's informed consent&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Male patients, not capable of complying the required preventive measures (see summary&#xD;
             of product characteristics Imnovid®)&#xD;
&#xD;
          -  Other criteria according to summary of product characteristics Imnovid®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tobias Dechow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>practice based oncology office Ravensburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iOMEDICO AG</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pomalidomide, Imnovid, dexamethasone, Poseidon, multiple myeloma, daily routine, secondary malignancies, Germany, non-interventional study, safety,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

